Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;34(9):1392-1398.
doi: 10.1002/mds.27807. Epub 2019 Jul 26.

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

Ilir Agalliu  1 , Roberto A Ortega  2 , Marta San Luciano  3 , Anat Mirelman  4 , Claustre Pont-Sunyer  5   6 , Kathrin Brockmann  7 , Dolores Vilas  5   8 , Eduardo Tolosa  5 , Daniela Berg  7   9 , Bjørg Warø  10 , Amanda Glickman  2 , Deborah Raymond  2 , Rivka Inzelberg  11 , Javier Ruiz-Martinez  12 , Elisabet Mondragon  12 , Eitan Friedman  13 , Sharon Hassin-Baer  11   14 , Roy N Alcalay  15 , Helen Mejia-Santana  15 , Jan Aasly  10 , Tatiana Foroud  16 , Karen Marder  15 , Nir Giladi  4 , Susan Bressman  2 , Rachel Saunders-Pullman  2
Affiliations

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

Ilir Agalliu et al. Mov Disord. 2019 Sep.

Abstract

Background: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls.

Methods: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients.

Results: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95% CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15-44.94) and colon cancer (OR = 2.34; 95% CI, 1.15-4.74) when compared with IPD patients.

Conclusions: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers. © 2019 International Parkinson and Movement Disorder Society.

Keywords: G2019S mutation; LRRK2 gene; Parkinson's disease; colon cancer; leukemia; pooled analysis.

PubMed Disclaimer

Conflict of interest statement

Relevant conflicts of interests Nothing to report.

References

    1. Devine MJ, Plun-Favreau H, Wood NW. Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer 2011;11(11):812–823. - PubMed
    1. D’Amelio M, Ragonese P, Sconzo G, Aridon P, Savettieri G. Parkinson’s disease and cancer: insights for pathogenesis from epidemiology. Ann N Y Acad Sci 2009;1155:324–334. - PubMed
    1. West AB, Dawson VL, Dawson TM. To die or grow: Parkinson’s disease and cancer. Trend Neurosci 2005;28(7):348–352. - PubMed
    1. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology 2009; 73(16):1286–1291. - PMC - PubMed
    1. Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011;76(23): 2002–2009. - PMC - PubMed

Publication types

MeSH terms

Substances